Skip to main content

Trypan Blue Ophthalmic Dosage

Applies to the following strengths: 0.06%; 0.15%

Usual Adult Dose for Ophthalmic Surgical Staining

0.06% ophthalmic solution:
0.3 mg injected into the anterior lens capsule via blunt cannula ONCE

Comments:

  • An air bubble should be injected into the anterior chamber after opening the eye to minimize dilution of this drug by the aqueous, then this drug should be injected.
  • Sufficient staining is achieved as soon as the dye has contacted the capsule.
  • The anterior chamber should be irrigated with a balanced salt solution to remove all excess dye
  • Cataract surgery (e.g., anterior capsulotomy) may then be performed.

Use: To aid in staining the anterior lens capsule during ophthalmic surgery

0.15% ophthalmic solution:
1.5 mg injected into the epiretinal membranes OR BSS-filled vitreous cavity via blunt cannula ONCE

Comments:
  • Syringes should be primed by ensuring that the plunger moves smoothly; the plunger should be retracted OR twisted clockwise prior to injection. The manufacturer product information should be consulted for further details regarding priming.
  • A "fluid-air exchange" (i.e., filling the entire vitreous cavity with air to prevent aqueous dilution of the drug) should be performed before injecting the drug, then the drug should be applied to the retinal membrane using a blunt cannula attached to the syringe, without allowing the cannula to contact or damage the retina.
  • Sufficient staining is expected on contact with the membrane.
  • Excessive dye should be removed from the vitreous cavity before performing an air-fluid exchange, to prevent unnecessary spreading of the dye.
  • This drug can also be injected directly in a BSS filled vitreous cavity (instead of injecting under air). After complete vitreous and posterior hyaloid removal, sufficient staining is achieved after 30 seconds of application under BSS.
  • This drug should be applied directly on the areas where membranes could be present, staining any portion of the membrane which contacts the dye; however, the dye does not penetrate the membrane.

Use: To aid and facilitate removal of epiretinal membranes via tissue staining during ophthalmic surgical vitrectomy procedures

Usual Pediatric Dose for Ophthalmic Surgical Staining

PEDIATRIC PATIENTS:
0.06% ophthalmic solution: 0.3 mg injected into the anterior lens capsule via blunt cannula ONCE

Comments:

  • An air bubble should be injected into the anterior chamber after opening the eye to minimize dilution of this drug by the aqueous, then this drug should be injected.
  • Sufficient staining is achieved as soon as the dye has contacted the capsule.
  • The anterior chamber should be irrigated with a balanced salt solution to remove all excess dye
  • Cataract surgery (e.g., anterior capsulotomy) may then be performed.

Use: To aid in staining the anterior lens capsule during ophthalmic surgery

0.15% ophthalmic solution: 1.5 mg injected into the epiretinal membranes OR BSS-filled vitreous cavity via blunt cannula ONCE

Comments:
  • Syringes should be primed by ensuring that the plunger moves smoothly; the plunger should be retracted OR twisted clockwise prior to injection. The manufacturer product information should be consulted for further details regarding priming.
  • A "fluid-air exchange" (i.e., filling the entire vitreous cavity with air to prevent aqueous dilution of the drug) should be performed before injecting the drug, then the drug should be applied to the retinal membrane using a blunt cannula attached to the syringe, without allowing the cannula to contact or damage the retina.
  • Sufficient staining is expected on contact with the membrane.
  • Excessive dye should be removed from the vitreous cavity before performing an air-fluid exchange, to prevent unnecessary spreading of the dye.
  • This drug can also be injected directly in a BSS filled vitreous cavity (instead of injecting under air). After complete vitreous and posterior hyaloid removal, sufficient staining is achieved after 30 seconds of application under BSS.
  • This drug should be applied directly on the areas where membranes could be present, staining any portion of the membrane which contacts the dye; however, the dye does not penetrate the membrane.

Use: To aid and facilitate removal of epiretinal membranes via tissue staining during ophthalmic surgical vitrectomy procedures

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

  • Use in patients with a planned insertion of a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL)

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Storage requirements:

  • Protect from direct sunlight.

Reconstitution/preparation techniques:
  • Syringes for 0.15% solutions should be primed by ensuring that the plunger moves smoothly: The plunger should be retracted OR twisted clockwise prior to injection. The manufacturer product information should be consulted for further details regarding priming.

Monitoring:
  • GENERAL/OCULAR: Excessive staining

Patient advice:
  • Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.